Literature DB >> 6701314

Tc-99m-galactosyl-neoglycoalbumin: in vivo characterization of receptor-mediated binding to hepatocytes.

D R Vera, K A Krohn, R C Stadalnik, P O Scheibe.   

Abstract

The biodistribution and kinetics of a receptor-binding hepatic radiopharmaceutical, Tc-99m-galactosyl-neoglycoalbumin (Tc-NGA), were investigated using mammalian and avian models. The radiopharmaceutical exhibited four significant features associated with receptor-mediated binding at the hepatocyte membrane in mammals: (a) high tissue specificity, (b) high molecular specificity, (c) affinity-dependent uptake, and (d) dose-dependent uptake. Diminished hepatic uptake by the avian model illustrated low nonspecific binding. The kinetic sensitivity to ligand-receptor affinity and stoichiometry illustrated the principal feature of receptor-binding radio-pharmaceuticals, namely, quantitative assessment of tissue function based upon the biochemical interaction of a ligand and its specific receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6701314     DOI: 10.1148/radiology.151.1.6701314

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

2.  The functional hepatic volume assessed by 99mTc-GSA hepatic scintigraphy.

Authors:  J Wu; N Ishikawa; T Takeda; Y Tanaka; X Q Pan; M Sato; T Todoroki; R Hatakeyama; Y Itai
Journal:  Ann Nucl Med       Date:  1995-11       Impact factor: 2.668

3.  Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass.

Authors:  M Kudo; A Todo; K Ikekubo; M Hino; Y Yonekura; K Yamamoto; K Torizuka
Journal:  Gastroenterol Jpn       Date:  1991-12

4.  Perioperative hepatic functional risk assessed with technetium-99m diethylenetriamine pentaacetic acid-galactosyl human serum albumin liver scintigraphy in patients undergoing pancreaticoduodenectomy complicated by obstructive jaundice.

Authors:  H Nakano; K Kumada; Y Takekuma; S Hasebe; Y Yoshizawa; M Yamaguchi; D Jaeck
Journal:  Int J Pancreatol       Date:  1999-02

5.  Functional liver imaging with asialoglycoprotein receptors and serum hyaluronate in a patient with amyloidosis.

Authors:  O Hashimoto; M Harada; M Sata; K Imamura; N Matsukuma; H Fukushima; S Itano; M Ohishi; T Ueno; A Iemura
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

6.  99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

Authors:  I Virgolini; P Angelberger; C Müller; J O'Grady; H Sinzinger
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

7.  Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.

Authors:  Roland Haubner; David R Vera; Salman Farshchi-Heydari; Anna Helbok; Christine Rangger; Daniel Putzer; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

Review 8.  ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images.

Authors:  Yuji Iimuro
Journal:  Visc Med       Date:  2017-11-22

9.  Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention.

Authors:  Kazuhiro Saito; Joseph Ledsam; Steven Sourbron; Tsuyoshi Hashimoto; Yoichi Araki; Soichi Akata; Koichi Tokuuye
Journal:  Eur Radiol       Date:  2013-08-15       Impact factor: 5.315

10.  Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept.

Authors:  Zhengtao Qin; Carl K Hoh; Emilia S Olson; Amin Haghighat Jahromi; David J Hall; Christopher V Barback; Young-Hyun You; Motoko Yanagita; Kumar Sharma; David R Vera
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.